Divi's Laboratories (NSE:DIVISLAB) Cyclically Adjusted PB Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
87 GF Score
Price ₹9,488.00
GF Value ₹7,250.06
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Divi's Laboratories Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Divi's Laboratories  (NSE:DIVISLAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Divi's Laboratories Cyclically Adjusted PB Ratio Related Terms


Divi's Laboratories Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Divi's Laboratories's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories Cyclically Adjusted PB Ratio Chart

Divi's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 17.80 14.84

Divi's Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 15.58 0.00 14.84 0.00

NSE:DIVISLAB vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Cyclically Adjusted PB Ratio falls into.


NSE:DIVISLAB
87GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Divi's Laboratories Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Divi's Laboratories's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Divi's Laboratories's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Divi's Laboratories Quarterly Data

Book Value per Share CPI Adj_Book
201203 80.293 76.889 174.767
201303 94.195 85.687 183.974
201403 111.627 91.425 204.338
201503 143.984 97.163 248.004
201603 161.725 102.518 264.010
201703 201.808 105.196 321.058
201803 223.182 109.786 340.216
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 262.070 118.202 371.054
201906 0.000 120.880 0.000
201909 266.606 123.175 362.236
201912 0.000 126.235 0.000
202003 275.359 124.705 369.539
202006 0.000 127.000 0.000
202009 313.525 130.118 403.255
202012 0.000 130.889 0.000
202103 350.120 131.771 444.676
202106 0.000 134.084 0.000
202109 374.024 135.847 460.780
202112 0.000 138.161 0.000
202203 441.791 138.822 532.603
202206 0.000 142.347 0.000
202209 457.103 144.661 528.819
202212 0.000 145.763 0.000
202303 480.922 146.865 548.027
202306 0.000 150.280 0.000
202309 477.532 151.492 527.542
202312 0.000 152.924 0.000
202403 511.208 153.035 559.053
202406 0.000 155.789 0.000
202409 516.708 157.882 547.718
202412 0.000 158.323 0.000
202503 563.870 157.552 598.964
202506 0.000 159.755 0.000
202509 580.595 162.289 598.726
202512 0.000 163.281 0.000
202603 631.373 164.272 643.230
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹9,488.00 is trading 30.9% above its estimated GF Value™ of ₹7,250.06. GuruFocus considers Divi's Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:DIVISLAB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹7,250.06 vs. price of ₹9,488.00 (30.9% above fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
87GF Score

Get the complete analysis for NSE:DIVISLAB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹9,488.00
Price
₹7,250.06
GF Value